Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hjermstad, M. J.
Right arrow Articles by Kaasa, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hjermstad, M. J.
Right arrow Articles by Kaasa, S.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 17, Issue 2 (February), 1999: 706
© 1999 American Society for Clinical Oncology

Health-Related Quality of Life 1 Year After Allogeneic or Autologous Stem-Cell Transplantation: A Prospective Study

Marianne J. Hjermstad, Stein A. Evensen, Stein O. Kvaløy, Peter M. Fayers, Stein Kaasa

From the Norwegian Cancer Society, Department of Oncology, Norwegian Radium Hospital, and Medical Department A, National Hospital, Oslo, Norway; Palliative Medicine Unit, Department of Oncology, Trondheim University Hospital, and Norwegian University of Science and Technology, Faculty of Medicine, Unit for Applied Clinical Research, Trondheim, Norway; and Medical Research Council Cancer Trials Office, Cambridge, United Kingdom.

Address reprint requests to Marianne Jensen Hjermstad, RN, MPH, Department of Oncology, The Norwegian Radium Hospital, Montebello, N-0310 Oslo, Norway; email mlhjerm{at}online.no

PURPOSE: To evaluate health-related quality of life (HRQOL) in adults treated with high-dose chemotherapy followed by allogeneic (SCT) and autologous (ASCT) stem-cell transplantation 1 year after transplantation, using data from concurrent lymphoma patients receiving combination chemotherapy (CT) as a reference.

MATERIALS AND METHODS: Forty-one leukemia patients (SCT group), 51 lymphoma patients (ASCT group), and 85 CT patients completed the European Organization for Research and Treatment of Cancer QLQ-C30 questionnaire at baseline and after 1 year.

RESULTS: The SCT group (median age, 36 years) had better functioning scores and less symptomatology at baseline compared with the ASCT (median age, 41 years) and CT (median age, 37 years) groups. Statistically significant differences of 10 or more points on the 0 to 100 scales were found for 10 of 15 scales and items (P <= .01) between the SCT and ASCT groups. Global quality of life (79 v 58, P < .0001), role function (83 v 65, P = .001), sleep disturbances (6 v 28, P < .0001), and fatigue (25 v 44, P = .0001) deviated most. The differences were 10 or more points for seven of 15 scales and items comparing the SCT and CT groups, with sleep disturbances (6 v 35, P < .0001) and pain (11 v 29, P < .01) deviating most. Differences across groups were smaller after 1 year; cognitive function was the only scale with a statistically significant difference (ASCT 80 v CT 89; P = .002).

Patterns of change in HRQOL scores were different between groups during follow-up. A great improvement was found in the ASCT group (P < .01 for emotional and role function, fatigue, appetite, and constipation), whereas no significant changes were observed for the SCT group.

CONCLUSION: Prospective studies with extended follow-up periods are necessary to separate a slow recovery process from more permanently reduced HRQOL after transplantation and to examine the late side effects from previous treatment.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
BloodHome page
J. Pidala, C. Anasetti, and H. Jim
Quality of life after allogeneic hematopoietic cell transplantation
Blood, July 2, 2009; 114(1): 7 - 19.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
K. A. Goodman, E. Riedel, V. Serrano, S. Gulati, C. H. Moskowitz, and J. Yahalom
Long-Term Effects of High-Dose Chemotherapy and Radiation for Relapsed and Refractory Hodgkin's Lymphoma
J. Clin. Oncol., November 10, 2008; 26(32): 5240 - 5247.
[Abstract] [Full Text] [PDF]


Home page
Arch Pediatr Adolesc MedHome page
K. K. Ness, S. Bhatia, K. S. Baker, L. Francisco, A. Carter, S. J. Forman, L. L. Robison, J. Rosenthal, and J. G. Gurney
Performance Limitations and Participation Restrictions Among Childhood Cancer Survivors Treated With Hematopoietic Stem Cell Transplantation: The Bone Marrow Transplant Survivor Study
Arch Pediatr Adolesc Med, August 1, 2005; 159(8): 706 - 713.
[Abstract] [Full Text] [PDF]


Home page
J Natl Cancer Inst MonogrHome page
L. M. Nail
My Get Up and Go Got Up and Went: Fatigue in People With Cancer
J Natl Cancer Inst Monographs, July 1, 2004; 2004(32): 72 - 75.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
K. L. Syrjala, S. L. Langer, J. R. Abrams, B. Storer, J. E. Sanders, M. E. D. Flowers, and P. J. Martin
Recovery and Long-term Function After Hematopoietic Cell Transplantation for Leukemia or Lymphoma
JAMA, May 19, 2004; 291(19): 2335 - 2343.
[Abstract] [Full Text] [PDF]


Home page
Palliat MedHome page
H. Knobel, J. H. Loge, E. Brenne, P. Fayers, M. J. Hjermstad, and S. Kaasa
The validity of EORTC QLQ-C30 fatigue scale in advanced cancer patients and cancer survivors
Palliative Medicine, December 1, 2003; 17(8): 664 - 672.
[Abstract] [PDF]


Home page
JCOHome page
Y. Brandberg, H. Michelson, B. Nilsson, C. Bolund, B. Erikstein, P. Hietanen, S. Kaasa, J. Nilsson, T. Wiklund, N. Wilking, et al.
Quality of Life in Women With Breast Cancer During the First Year After Random Assignment to Adjuvant Treatment With Marrow-Supported High-Dose Chemotherapy With Cyclophosphamide, Thiotepa, and Carboplatin or Tailored Therapy With Fluorouracil, Epirubicin, and Cyclophosphamide: Scandinavian Breast Group Study 9401
J. Clin. Oncol., October 1, 2003; 21(19): 3659 - 3664.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
K. Hartl, W. Janni, R. Kastner, H. Sommer, B. Strobl, B. Rack, and M. Stauber
Impact of medical and demographic factors on long-term quality of life and body image of breast cancer patients
Ann. Onc., July 1, 2003; 14(7): 1064 - 1071.
[Abstract] [Full Text] [PDF]


Home page
CA Cancer J ClinHome page
H. Kattlove and R. J. Winn
Ongoing Care of Patients After Primary Treatment for Their Cancer
CA Cancer J Clin, May 1, 2003; 53(3): 172 - 196.
[Abstract] [Full Text] [PDF]


Home page
Palliat MedHome page
S. Kaasa and J. H. Loge
Quality of life in palliative care: principles and practice
Palliative Medicine, January 1, 2003; 17(1): 11 - 20.
[Abstract] [PDF]


Home page
Ann OncolHome page
M. Hensel, G. Egerer, A. Schneeweiss, H. Goldschmidt, and A. D. Ho
Quality of life and rehabilitation in social and professional life after autologous stem cell transplantation
Ann. Onc., February 20, 2002; 13(2): 209 - 217.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
W. Janni, D. Rjosk, Th. Dimpfl, K. Haertl, B. Strobl, F. Hepp, A. Hanke, F. Bergauer, and H. Sommer
Quality of Life Influenced by Primary Surgical Treatment for Stage I-III Breast Cancer--Long-Term Follow-Up of a Matched-Pair Analysis
Ann. Surg. Oncol., July 1, 2001; 8(6): 542 - 548.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. J. Lee, D. Fairclough, S. K. Parsons, R. J. Soiffer, D. C. Fisher, R. L. Schlossman, J. H. Antin, and J. C. Weeks
Recovery After Stem-Cell Transplantation for Hematologic Diseases
J. Clin. Oncol., January 1, 2001; 19(1): 242 - 252.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
N. Mounier, C. Haioun, B. F. Cole, C. Gisselbrecht, C. Sebban, P. Morel, G. Marit, R. Bouabdallah, C. Ravoet, G. Salles, et al.
Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission
Blood, June 15, 2000; 95(12): 3687 - 3692.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 1999 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online